StockData

Ironwood Pharmaceuticals vs Ultragenyx Pharmaceutical

IRWD and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRWD and RARE compare

Ultragenyx Pharmaceutical is the larger company, worth 2.1 times as much as Ironwood Pharmaceuticals ($1.6B against $801M).

Ironwood Pharmaceuticals grew revenue faster over the last twelve months (26.2% versus 17.5% for Ultragenyx Pharmaceutical).

Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −81.7% at Ultragenyx Pharmaceutical.

Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRWDRARE
Size and price
Market cap$801M$1.6B
Share price$4.85$16.70
Change, 1 year43.9%−49.5%
Change, 5 years−56.5%−78.2%
Beta (5Y)1.052.12
Employees1001,371
StockData Score
Total score12 (better)9
Valuation score6 (better)1
Growth score22
Performance score2 (better)1
Health score25 (better)
Dividend score00
Valuation
P/E6.3×–
P/S2.1× (better)2.3×
EV/EBITDA3.1×–
FCF yield–−29.7%
Fair value$12.87–
Margin of safety62.3%–
Growth
Revenue growth (TTM)26.2% (better)17.5%
Revenue growth, 5Y average−5.3%19.9% (better)
EPS growth, 5Y average−25.6%–
Profitability
Operating margin60.1% (better)−73.6%
Net margin33.4% (better)−81.7%
FCF margin–−68.2%
Financial health
Interest coverage7.2×–
Current ratio6.06 (better)1.73
Altman Z-score−1.91 (better)−5.26
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.2%108%
Held by insiders16.0%4.0%
Insider net buying, 12 months−$22.6M−$3.8M (better)
Short interest, % of float10.7%25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.